Low Expression Indicates a Biomarker of Poor Prognosis in Patients with Renal Cell Carcinoma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2021 Apr 9

PMID 33834072

Citations 2

Authors

Chaoxiang Lv

Yuanguo Li

Qiqi Zhang

Yanyan Chen

Dandan Wei

Tiecheng Wang

Bo Zhou

Affiliations

Soon will be listed here.

Abstract

It was initially found that neural-restrictive silencer factor/repressor 1-silencing transcription factor () is a transcriptional repressor of neuronal genes in nonneuronal cells. However, it is reported to be abundantly expressed in various types of aggressive cancer cells. In this study, we evaluated the expression patterns of in renal cell carcinoma and found that its expression is lower in tumor tissues compared to normal tissues. The chi-square test showed that the low expression was closely related to patients' clinicopathologic parameters, including the pathologic stage and survival status. ROC curve showed that had excellent clinical diagnostic prospect. In addition, patients with low expression had poor over survival (OS) and relapse-free survival (RFS). Univariate and multivariate Cox regression analysis confirmed that the low expression was an independent predictor of poor prognosis in renal cell carcinoma. Gene set enrichment analysis identified P53 pathway, reactive oxygen species pathway, glycolysis, DNA repair, cholesterol homeostasis, and MYC targets V2 enriched with low expression phenotype. These results suggested that may be a novel biomarker for the diagnosis and prognosis of renal cell carcinoma in clinical applications.

Citing Articles

TMX family genes and their association with prognosis, immune infiltration, and chemotherapy in human pan-cancer.

Luo N, Mei Z, Zhang Q, Tang H, Wan R, Deng A Aging (Albany NY). 2023; 15(24):15064-15083.

PMID: 38147024 PMC: 10781458. DOI: 10.18632/aging.205332.

Protein Expression of NEK2, JMJD4, and REST in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical, Pathological, and Prognostic Findings.

Elsayed W, Harb O, Alabiad M, Faraj Saad R, Anbaig A, Alorini M Iran J Pathol. 2023; 18(2):180-192.

PMID: 37600577 PMC: 10439757. DOI: 10.30699/IJP.2023.1974154.3022.

References

Alshawli A, Wurdak H, Wood I, Ladbury J . Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes. Mol Genet Genomic Med. 2020; 8(10):e1429. PMC: 7549561. DOI: 10.1002/mgg3.1429. View

Rockowitz S, Zheng D . Significant expansion of the REST/NRSF cistrome in human versus mouse embryonic stem cells: potential implications for neural development. Nucleic Acids Res. 2015; 43(12):5730-43. PMC: 4499139. DOI: 10.1093/nar/gkv514. View

Taylor P, Fangusaro J, Rajaram V, Goldman S, Helenowski I, MacDonald T . REST is a novel prognostic factor and therapeutic target for medulloblastoma. Mol Cancer Ther. 2012; 11(8):1713-1723. PMC: 3763747. DOI: 10.1158/1535-7163.MCT-11-0990. View

Gray R, Harris G . Renal Cell Carcinoma: Diagnosis and Management. Am Fam Physician. 2019; 99(3):179-184. View

Singh S, Kagalwala M, Parker-Thornburg J, Adams H, Majumder S . REST maintains self-renewal and pluripotency of embryonic stem cells. Nature. 2008; 453(7192):223-7. PMC: 2830094. DOI: 10.1038/nature06863. View

Epping M, Lunardi A, Nachmani D, Castillo-Martin M, Thin T, Cordon-Cardo C . TSPYL2 is an essential component of the REST/NRSF transcriptional complex for TGFβ signaling activation. Cell Death Differ. 2015; 22(8):1353-62. PMC: 4495358. DOI: 10.1038/cdd.2014.226. View

Perazella M, Dreicer R, Rosner M . Renal cell carcinoma for the nephrologist. Kidney Int. 2018; 94(3):471-483. DOI: 10.1016/j.kint.2018.01.023. View

Kong Q, Xie B, Zhang H, Li J, Huang T, Wei R . RE1-silencing Transcription Factor (REST) Is Required for Nuclear Reprogramming by Inhibiting Transforming Growth Factor β Signaling Pathway. J Biol Chem. 2016; 291(53):27334-27342. PMC: 5207159. DOI: 10.1074/jbc.M116.743849. View

Tariq N, Mamoon N, Haroon A, Ali Z, Ahmad I . Role Of Immunohistochemistry In Subtyping Renal Cell Carcinomas With Overlapping Morphological Features. J Ayub Med Coll Abbottabad. 2018; 30(3):325-332. View

10.

Nam D . Effect of the absolute statistic on gene-sampling gene-set analysis methods. Stat Methods Med Res. 2015; 26(3):1248-1260. DOI: 10.1177/0962280215574014. View

11.

Richter I, Dvorak J . [Treatment of Metastatic Renal Cell Carcinoma]. Klin Onkol. 2018; 31(2):110-116. DOI: 10.14735/amko2018110. View

12.

Kim H, Denli A, Wright R, Baul T, Clemenson G, Morcos A . REST Regulates Non-Cell-Autonomous Neuronal Differentiation and Maturation of Neural Progenitor Cells via Secretogranin II. J Neurosci. 2015; 35(44):14872-84. PMC: 4635134. DOI: 10.1523/JNEUROSCI.4286-14.2015. View

13.

Shudo Y, Shimojo M, Fukunaga M, Ito S . Pituitary adenylate cyclase-activating polypeptide is regulated by alternative splicing of transcriptional repressor REST/NRSF in nerve injury. Life Sci. 2015; 143:174-81. DOI: 10.1016/j.lfs.2015.10.033. View

14.

Shimojo M, Lee J, Hersh L . Role of zinc finger domains of the transcription factor neuron-restrictive silencer factor/repressor element-1 silencing transcription factor in DNA binding and nuclear localization. J Biol Chem. 2001; 276(16):13121-6. DOI: 10.1074/jbc.M011193200. View

15.

Nakano Y, Kelly M, Rehman A, Boger E, Morell R, Kelley M . Defects in the Alternative Splicing-Dependent Regulation of REST Cause Deafness. Cell. 2018; 174(3):536-548.e21. PMC: 6370011. DOI: 10.1016/j.cell.2018.06.004. View

16.

Jiao Y, Fu Z, Li Y, Zhang W, Liu Y . Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. PLoS One. 2019; 14(1):e0211291. PMC: 6351057. DOI: 10.1371/journal.pone.0211291. View

17.

DAlessandro R, Meldolesi J . In PC12 cells, expression of neurosecretion and neurite outgrowth are governed by the transcription repressor REST/NRSF. Cell Mol Neurobiol. 2010; 30(8):1295-302. PMC: 11498750. DOI: 10.1007/s10571-010-9602-0. View

18.

Ravanpay A, Hansen S, Olson J . Transcriptional inhibition of REST by NeuroD2 during neuronal differentiation. Mol Cell Neurosci. 2010; 44(2):178-89. PMC: 2866295. DOI: 10.1016/j.mcn.2010.03.006. View

19.

Gao S, Zhao X, Lin B, Hu Z, Yan L, Gao J . Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance. Tumour Biol. 2012; 33(5):1759-65. DOI: 10.1007/s13277-012-0435-y. View

20.

Courthod G, Tucci M, Di Maio M, Scagliotti G . Papillary renal cell carcinoma: A review of the current therapeutic landscape. Crit Rev Oncol Hematol. 2015; 96(1):100-12. DOI: 10.1016/j.critrevonc.2015.05.008. View